Funding Support Center
DF/HCC Sponsored Funding
Dana-Farber/Harvard Cancer Center (DF/HCC) Sponsored Funding
Sponsor: Non-federal (DFCI)
One page Letter of Intent due by March 5, 2012. Submit letter online: Application Form Web Page
Submission requirements: Applications must be submitted online: Application Form Web Page
Please direct questions to:
Lupron-Treatable Disease and Conditions Awards will support investigators who are focused on non Prostate Cancer diseases and conditions that are Lupron-treatable, including but not limited to endometriosis, uterine fibroids, and precocious (early-onset) puberty in both male and female children. Projects may focus on lab and translational research to examine innovative treatment alternatives. Examples of disciplines relevant to this RFA include any aspect of prevention (health promotion, modifiable risk factors, behavioral research, and behavioral intervention trials), epidemiology (classic, genetic, molecular), biostatistics, human cancer genetics, human nutrition, health services and health policy research, medical decision analysis, survivorship and quality of life; and basic and applied research in the behavioral sciences that independently or in combination with biomedical approaches, reduces disease risk, incidence, morbidity, and mortality from primary behavioral prevention in youth, to screening, treatment, and survivorship. Projects should develop preliminary data necessary to prepare and submit a competitive research grant application to a major funding agency.
Award is for $50,000 per year for up to two years ($100,000 total in direct costs). The next projected award period is July 1, 2012 to June 30, 2014. Two awards remain in this category to be awarded over a four-year period.
Funding Agency: The funding agency for the program is a grant from the U.S. District Court for the District of Massachusetts. Funding was derived from a pool of unclaimed funds from the settlement in 2004 of a class action suit against TAP Pharmaceuticals. The class action suit was related to marketing and sales practices for the prostate cancer drug Lupron.
The Mazzone Awards Program is a DFCI sponsored award, administered jointly through DF/HCC and the Prostate Cancer Foundation.
Applications will be accepted from two or more independent investigators, at least one of whom holds a full-time appointment on the faculty at Harvard or at any other accredited Massachusetts university, at the level of Instructor or higher. Applicants from institutions throughout the country are encouraged to apply as long as they have a collaborator in a university in Massachusetts. Applicants may apply for multiple grants; however, individuals may only be awarded one A. David Mazzone Research Award at a time.
Employees or subcontractors of a government entity or for-profit private industry are not eligible. Exceptions include applicants holding full-time positions at a veterans' hospital or national laboratory (e.g., Lawrence Berkeley National Laboratory) in the United States. Members of the Programís Scientific Advisory Board (SAB) are ineligible to apply.
PROPOSAL SUBMISSION INFORMATION
Format: Items 2 Ė 4 (above) must be compiled and submitted as a single PDF file. Please include the PIís name, project title, and page number at the top of each page.
Submit Proposal Online: Application Form Web Page
2011 Lupron treatable disease and conditions Mazzone Awards Recipients
Cancer and Endometriosis
Endometriosis is a prevalent gynecologic disease, for which Lupron is a primary treatment, which is marked by unclear etiology and signs and symptoms that can be physically debilitating and correlated with infertility. Emerging hospital discharge and case-control data suggest that women with endometriosis may be at greater risk of hormonal and inflammatory-related cancers, with breast cancer, ovarian cancer, and melanoma risk most consistently observed. However, data have not been available to address these relations with a time-dependent approach and accounting for the potential correlation of risk factors and impact of treatment. This project will utilize the more than 20 years of prospectively collected data from the Nurses' Health Study II that began in 1989 when nearly 120,000 women were enrolled -- among whom 8000 laparoscopically-confirmed endometriosis cases have been incidentally diagnosed. Successful completion of these aims may advance our understanding of the etiologies of endometriosis and these cancers and form the basis for public health interventions that can promote earlier detection in these women at greater risk. This study will further collaborative work on the genetic basis of endometriosis at Oxford University as well as inform additional collaborative ongoing investigations of cytoskeletal protein mutations associated with breast cancer and endometriosis at MIT.